Peter Hall
@peterhall001.bsky.social
Breast Oncologist and Professor of Cancer Informatics, Edinburgh | Health Economics | Real World Evidence | https://cancer-data.ecrc.ed.ac.uk/
Pinned
Peter Hall
@peterhall001.bsky.social
· Nov 18
DataLoch, in collaboration with ECi are proud to announce our membership of the UK RWE Network. Operated by HDR UK, we aim to prove the potential of Observational Medical Outcomes Partnership (OMOP) and the Common Data Model (CDM).
Find out more below👇🏼
t.co/rj89DIgT4b
Find out more below👇🏼
t.co/rj89DIgT4b
Reposted by Peter Hall
The TARGET reporting guidelines for target trial emulation studies have arrived!
#EpiSky #CausalSky
jamanetwork.com/journals/jam...
#EpiSky #CausalSky
jamanetwork.com/journals/jam...
TARGET 2025 Statement
This Special Communication introduces the Transparent Reporting of Observational Studies Emulating a Target Trial (TARGET) 2025 guideline, a consensus-based guidance for reporting observational studie...
jamanetwork.com
September 3, 2025 at 4:20 PM
The TARGET reporting guidelines for target trial emulation studies have arrived!
#EpiSky #CausalSky
jamanetwork.com/journals/jam...
#EpiSky #CausalSky
jamanetwork.com/journals/jam...
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial - The Lancet www.thelancet.com/journals/lan...
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised ...
The addition of adjuvant chemotherapy to hormonotherapy conferred no survival benefit
in women aged 70 years and above with a GGI high-risk oestrogen receptor-positive
HER2-negative breast cancer, and...
www.thelancet.com
August 29, 2025 at 9:17 AM
Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial - The Lancet www.thelancet.com/journals/lan...
Reposted by Peter Hall
In this blog, Jack Elliott and Elaine Kelly examine trends in unpaid overtime among NHS staff since 2019 and consider the implications for future productivity.
Read more ⬇️
https://bit.ly/4mILY3C
Read more ⬇️
https://bit.ly/4mILY3C
August 29, 2025 at 9:00 AM
In this blog, Jack Elliott and Elaine Kelly examine trends in unpaid overtime among NHS staff since 2019 and consider the implications for future productivity.
Read more ⬇️
https://bit.ly/4mILY3C
Read more ⬇️
https://bit.ly/4mILY3C
Preprint "The C-Index Multiverse" arxiv.org/abs/2508.14821
The C-index Multiverse
Quantifying out-of-sample discrimination performance for time-to-event outcomes is a fundamental step for model evaluation and selection in the context of predictive modelling. The concordance index, ...
arxiv.org
August 21, 2025 at 7:44 AM
Preprint "The C-Index Multiverse" arxiv.org/abs/2508.14821
Reposted by Peter Hall
Target trial emulation is an important, useful idea, but we must remain careful to not allow novices to think it's a magical shortcut to causal inference. Nor can we lose sight of the *main* thing that separates randomized from non-randomized studies.
August 12, 2025 at 10:15 AM
Target trial emulation is an important, useful idea, but we must remain careful to not allow novices to think it's a magical shortcut to causal inference. Nor can we lose sight of the *main* thing that separates randomized from non-randomized studies.
Reposted by Peter Hall
Do. Not. Give. This. To. The. Medics. PLEASE.
Introducing my new #rstats package {kitchensink}
Not sure what the right model to fit is? Should you allow random intercepts, slopes, both? What do Bayesian methods say?
Just call {kitchensink::throw} to fit every possible model and see how your results differ!
Not sure what the right model to fit is? Should you allow random intercepts, slopes, both? What do Bayesian methods say?
Just call {kitchensink::throw} to fit every possible model and see how your results differ!
July 16, 2025 at 1:54 PM
Do. Not. Give. This. To. The. Medics. PLEASE.
Reposted by Peter Hall
Vaginal estrogen therapy initiation after breast cancer and oncological outcomes: a nationwide population-based target trial emulation. https://www.medrxiv.org/content/10.1101/2024.10.23.24315966v1
Vaginal estrogen therapy initiation after breast cancer and oncological outcomes: a nationwide population-based target trial emulation. https://www.medrxiv.org/content/10.1101/2024.10.23.24315966v1
Background: Genitourinary syndrome of menopause (GSM) frequently occurs after breast cancer (BC), le
www.medrxiv.org
October 24, 2024 at 5:30 PM
Vaginal estrogen therapy initiation after breast cancer and oncological outcomes: a nationwide population-based target trial emulation. https://www.medrxiv.org/content/10.1101/2024.10.23.24315966v1
Reposted by Peter Hall
We're hiring!
A vacancy has opened up in the team for the position of Post-Doctoral Research Fellow. 🔬 🧑🏼💻
If this sounds like something you'd be interested in, details can be found on our website below. 👇
cancer-data.ecrc.ed.ac.uk/2025/03/07/r...
A vacancy has opened up in the team for the position of Post-Doctoral Research Fellow. 🔬 🧑🏼💻
If this sounds like something you'd be interested in, details can be found on our website below. 👇
cancer-data.ecrc.ed.ac.uk/2025/03/07/r...
March 7, 2025 at 12:23 PM
We're hiring!
A vacancy has opened up in the team for the position of Post-Doctoral Research Fellow. 🔬 🧑🏼💻
If this sounds like something you'd be interested in, details can be found on our website below. 👇
cancer-data.ecrc.ed.ac.uk/2025/03/07/r...
A vacancy has opened up in the team for the position of Post-Doctoral Research Fellow. 🔬 🧑🏼💻
If this sounds like something you'd be interested in, details can be found on our website below. 👇
cancer-data.ecrc.ed.ac.uk/2025/03/07/r...
Reposted by Peter Hall
Haven't registered your place for the Beatson International Cancer Conference 2025 yet? Find out what delegates had to say about last year's event
📅Register by 21 March: beatsonconference.org
#BICC2025
📅Register by 21 March: beatsonconference.org
#BICC2025
February 27, 2025 at 10:01 AM
Haven't registered your place for the Beatson International Cancer Conference 2025 yet? Find out what delegates had to say about last year's event
📅Register by 21 March: beatsonconference.org
#BICC2025
📅Register by 21 March: beatsonconference.org
#BICC2025
Today is the 4th Edinburgh Breast Cancer Special Symposium #EBCSS25 www.ebcss.org
Home | EBCSS 2025 Edinburgh
EBCSS Edinburgh International Breast Cancer Conference
www.ebcss.org
February 21, 2025 at 7:29 AM
Today is the 4th Edinburgh Breast Cancer Special Symposium #EBCSS25 www.ebcss.org
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer www.nature.com/articles/s41...
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer - npj Breast Cancer
npj Breast Cancer - A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer
www.nature.com
February 16, 2025 at 7:10 PM
A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer www.nature.com/articles/s41...
Reposted by Peter Hall
📌 Adjuvant Atezolizumab for Early Triple-Negative Breast CancerThe ALEXANDRA/IMpassion030 Randomized Clinical Trial
jamanetwork.com/journals/jama/…
@oncoalert.bsky.social
jamanetwork.com/journals/jama/…
@oncoalert.bsky.social
January 30, 2025 at 9:59 PM
📌 Adjuvant Atezolizumab for Early Triple-Negative Breast CancerThe ALEXANDRA/IMpassion030 Randomized Clinical Trial
jamanetwork.com/journals/jama/…
@oncoalert.bsky.social
jamanetwork.com/journals/jama/…
@oncoalert.bsky.social
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial - The Lancet www.thelancet.com/journals/lan...
January 31, 2025 at 8:10 AM
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial - The Lancet www.thelancet.com/journals/lan...
Reposted by Peter Hall
Together with the NIHR (National Institute for Health and Care Research), the EPSRC, Health Data Research UK (HDR UK) and ADR UK (Administrative Data Research UK), we’re announcing a £10m programme which will help identify individual cancer risk 🙌
Read more 👉 cruk.ink/42q0aaY
Read more 👉 cruk.ink/42q0aaY
£10m funding for new programme to help identify individual cancer risk - Cancer Research UK - Cancer News
Today, Cancer Research UK, the NIHR and the EPSRC are announcing £10 million to create the Cancer Data-Driven Detection programme
cruk.ink
January 22, 2025 at 10:02 AM
Together with the NIHR (National Institute for Health and Care Research), the EPSRC, Health Data Research UK (HDR UK) and ADR UK (Administrative Data Research UK), we’re announcing a £10m programme which will help identify individual cancer risk 🙌
Read more 👉 cruk.ink/42q0aaY
Read more 👉 cruk.ink/42q0aaY
Reposted by Peter Hall
So happy to share the latest study from NOTCH led by Dr Karen Mactier from @NHS_Lothian @UofGlasgow, looking at UK-wide practice in managing a rare cancer, uterine sarcoma
👇👇👇
pubmed.ncbi.nlm.nih.gov/39725428/
👇👇👇
pubmed.ncbi.nlm.nih.gov/39725428/
TOURISM study (Treatment Outcomes in UteRIne SarcoMa): a 10-year retrospective evaluation of practice in the UK - PubMed
Our data highlight the diversity in patient management in uterine sarcoma and a marked survival advantage for patients diagnosed with stage I disease. These data highlight the importance of a multidis...
pubmed.ncbi.nlm.nih.gov
January 6, 2025 at 10:06 AM
So happy to share the latest study from NOTCH led by Dr Karen Mactier from @NHS_Lothian @UofGlasgow, looking at UK-wide practice in managing a rare cancer, uterine sarcoma
👇👇👇
pubmed.ncbi.nlm.nih.gov/39725428/
👇👇👇
pubmed.ncbi.nlm.nih.gov/39725428/
Reposted by Peter Hall
Are you a health economist, epidemiologist or data scientist with experience using routine healthcare data? Interested in equity in cancer care? Come and join this exciting @nihr.bsky.social funded project! Work with a range of stakeholders and build your skills. jobs.leeds.ac.uk/Vacancy.aspx...
Job Opportunity at University of Leeds: Research Fellow
Are you an ambitious researcher looking for your next challenge? Do you have a background in economics, econometrics, statistics, epidemiology or health data science? Are you interested in working wit...
jobs.leeds.ac.uk
January 6, 2025 at 9:40 AM
Are you a health economist, epidemiologist or data scientist with experience using routine healthcare data? Interested in equity in cancer care? Come and join this exciting @nihr.bsky.social funded project! Work with a range of stakeholders and build your skills. jobs.leeds.ac.uk/Vacancy.aspx...
Reposted by Peter Hall
4w Denosumab or 12w
The efficacy results of the REDUSE study are not mature yet but the tox results are in
Less drug - fewer tox events
ONJ all grades 8.1 vs 5.2%
#SABCS24
The efficacy results of the REDUSE study are not mature yet but the tox results are in
Less drug - fewer tox events
ONJ all grades 8.1 vs 5.2%
#SABCS24
December 11, 2024 at 1:33 PM
4w Denosumab or 12w
The efficacy results of the REDUSE study are not mature yet but the tox results are in
Less drug - fewer tox events
ONJ all grades 8.1 vs 5.2%
#SABCS24
The efficacy results of the REDUSE study are not mature yet but the tox results are in
Less drug - fewer tox events
ONJ all grades 8.1 vs 5.2%
#SABCS24
#SABCS24 FDA session highlighting need to consider Minimum Effictive Dose, not just Maximum Tolerated Dose. Reminds me of the GO2 trial in gastric ca last decade. Breast cancer drug development catching up? jamanetwork.com/journals/jam...
Efficacy of Reduced-Intensity Chemotherapy Among Older and Frail Patients With Advanced Gastroesophageal Cancer
This randomized clinical trial assesses the efficacy of reduced-intensity chemotherapy for patient quality of life and cancer control in the treatment of older and/or frail patients.
jamanetwork.com
December 10, 2024 at 7:34 PM
#SABCS24 FDA session highlighting need to consider Minimum Effictive Dose, not just Maximum Tolerated Dose. Reminds me of the GO2 trial in gastric ca last decade. Breast cancer drug development catching up? jamanetwork.com/journals/jam...
The Sudlow Review on the challenges and opportunities for using UK linked healthcare data for research www.hdruk.ac.uk/helping-with...
www.hdruk.ac.uk
December 2, 2024 at 10:34 AM
The Sudlow Review on the challenges and opportunities for using UK linked healthcare data for research www.hdruk.ac.uk/helping-with...
Reposted by Peter Hall
Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
November 30, 2024 at 12:54 PM
Our latest in @naturecomms.bsky.social from @danafarber.bsky.social / @mskcc.bsky.social collaboration: AI to extract cancer outcomes in EMR!
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Very good to see more de-escalation trials publishing in HER2 positive early breast cancer. Here the HELEN-006 trial. www.thelancet.com/journals/lan...
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006)...
These findings might suggest a potential advantage of nab-paclitaxel combined with
trastuzumab and pertuzumab compared with the standard regimen in neoadjuvant therapy
for patients with HER2-positive ...
www.thelancet.com
November 29, 2024 at 7:48 AM
Very good to see more de-escalation trials publishing in HER2 positive early breast cancer. Here the HELEN-006 trial. www.thelancet.com/journals/lan...
Reposted by Peter Hall
📣 Check out this recent study:
UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study
From @drmarkbaxter.bsky.social and colleagues: bmjoncology.bmj.com/content/3/1/...
#cancer #chemotherapy
UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study
From @drmarkbaxter.bsky.social and colleagues: bmjoncology.bmj.com/content/3/1/...
#cancer #chemotherapy
UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study
Objective The Cancer and Aging Research Group (CARG) score was developed to predict severe chemotherapy-induced toxicity risk in older adults; validation study results have varied. The Tolerance of An...
bmjoncology.bmj.com
November 28, 2024 at 1:33 PM
📣 Check out this recent study:
UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study
From @drmarkbaxter.bsky.social and colleagues: bmjoncology.bmj.com/content/3/1/...
#cancer #chemotherapy
UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study
From @drmarkbaxter.bsky.social and colleagues: bmjoncology.bmj.com/content/3/1/...
#cancer #chemotherapy
This is how we should be doing Oncology trials - the Dutch SONIA trial looking at treatment sequencing of CDK 4/6 inhibitors in advanced breast cancer. A self funding efficiency trial! #oncsky www.nature.com/articles/s41...
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
www.nature.com
November 27, 2024 at 7:24 PM
This is how we should be doing Oncology trials - the Dutch SONIA trial looking at treatment sequencing of CDK 4/6 inhibitors in advanced breast cancer. A self funding efficiency trial! #oncsky www.nature.com/articles/s41...
Reposted by Peter Hall
Our latest mixed-methods paper in #bmjopen describes where cancer patients and staff found benefit in using an eHealth #proms based intervention as part of routine care during systemic/chemo treatment. bmjopen.bmj.com/content/bmjo...
November 16, 2024 at 8:18 AM
Our latest mixed-methods paper in #bmjopen describes where cancer patients and staff found benefit in using an eHealth #proms based intervention as part of routine care during systemic/chemo treatment. bmjopen.bmj.com/content/bmjo...